Persistent Tumor Mutational Burden (pTMB) May Predict Response to Immune Checkpoint Inhibitors

Clin Chem. 2024 Jan 4;70(1):25-26. doi: 10.1093/clinchem/hvad128.
No abstract available

MeSH terms

  • Humans
  • Immune Checkpoint Inhibitors* / therapeutic use
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics

Substances

  • Immune Checkpoint Inhibitors